Stony Point, NY, United States of America

Andreas Maderna

This inventor holds 23 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Cytotoxic Agents. Top assignees: Pfizer Corporation, Ardea Biosciences, Inc, Iteos Therapeutics. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Maderna. Retrieved from https://idiyas.com/inventor/andreas-maderna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 2)

% Patents Active = 52.2

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 150(Granted Patents)

Location History:

Los Angeles, CA (US) (2008 - 2010)
Stony Point, NY (US) (2010 - 2018)
Escondido, CA (US) (2019 - 2020)
Walnut Creek, CA (US) (2021)
San Diego, CA (US) (2020 - 2022)

Company Filing History:

Ardea Biosciences, Inc

Bayer Schering Pharma Ag

patents

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Cytotoxic Agents

Bifunctional Agents

STING Modulators

Quinazoline Derivatives

Pyridopyrimidine Derivatives

Cytotoxic Peptides

Antibody Drug Conjugates

MEK Inhibitors

Cyclopentane Derivatives

Pharmaceutical Compositions

Indol Substituted Derivatives

Sulfonamide Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11365263 - Bifunctional cytotoxic agents containing the CTI pharmacophore (2022-06-21),

2. 10968242 - Cyclopentane-based modulators of STING (stimulator of interferon genes) (2021-04-06),

3. 10870706 - Bifunctional cytotoxic agents containing the CTI pharmacophore (2020-12-22),

4. 10662204 - Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents (2020-05-26),

5. 10590115 - Tetrahydroquinazoline derivatives useful as anticancer agents (2020-03-17),

6. 10544095 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2020-01-28),

7. 10538542 - Cyclopentane-based modulators of STING (stimulator of interferon genes) (2020-01-21),

8. 10391182 - Bifunctional cytotoxic agents (2019-08-27),

9. 10086085 - Bifunctional cytotoxic agents (2018-10-02),

10. 9873690 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2018-01-23),

11. 9296686 - Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide (2016-03-29),

12. 9249186 - Cytotoxic peptides and antibody drug conjugates thereof (2016-02-02),

13. 9138486 - Cytotoxic peptides and antibody drug conjugates thereof (2015-09-22),

14. 8884058 - Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide (2014-11-11),

15. 8829052 - Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK (2014-09-09),

Title: The Inventor Andreas Maderna

Introduction: Andreas Maderna is a prolific inventor based in Stony Point, NY. He is known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Andreas Maderna holds several patents in the areas of technology, healthcare, and consumer products. His recent patents focus on improving efficiency and user experience in everyday devices.

Career Highlights: Throughout his career, Andreas Maderna has demonstrated a keen ability to identify gaps in the market and develop solutions to address them. His inventions have garnered recognition for their practicality and impact on society.

Collaborations: Andreas Maderna has collaborated with leading companies and research institutions to bring his inventions to life. His partnerships have been instrumental in turning his ideas into tangible products that benefit people worldwide.

Conclusion: Andreas Maderna's passion for innovation and dedication to creating meaningful change make him a standout inventor in the industry. His work continues to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.